Trial Profile
Open-label, Single-arm, Multiple-dose Safety, Titration, and Pharmacokinetic Trial of Afrezza in Pediatric Patients Ages 4 to 17 Years With Type 1 Diabetes Mellitus
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 25 Jan 2023
Price :
$35
*
At a glance
- Drugs Insulin (Primary)
- Indications Type 1 diabetes mellitus
- Focus Adverse reactions
- Sponsors MannKind Corporation
- 18 Jan 2023 Results reporting time-action profiles of Technosphere Insulin in children with type 1 diabetes published in the Diabetes Therapy
- 25 Jun 2021 According to a MannKind Corporation media release, data from this trial will be presented at the American Diabetes Association's virtual 81st Scientific Sessions
- 15 Sep 2020 Status changed from recruiting to completed.